Drug prescription in mild cognitive impairment: The physicians' perspective in Italy

International Journal of Geriatric Psychiatry

Volumn 21, Issue 11, 2006, Pages 1071-1077

  Frisoni, Giovanni B ^a   Canu, Elisa ^a   Geroldi, Cristina ^a   Zanetti, Orazio ^a   Zacchi, Valeria ^a  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

Author keywords

Alzheimer's disease; Drug therapy; Mild cognitive impairment; UVA

Indexed keywords

ALPHA TOCOPHEROL; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CHOLINESTERASE INHIBITOR; GINKGO BILOBA EXTRACT; NEUROLEPTIC AGENT; NOOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; DISEASE SEVERITY; GINKGO BILOBA; HUMAN; ITALY; MINI MENTAL STATE EXAMINATION; PRESCRIPTION; STRUCTURED QUESTIONNAIRE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; FEMALE; GINKGO BILOBA; HUMANS; ITALY; MALE; MIDDLE AGED; NOOTROPIC AGENTS; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; VITAMIN E; VITAMINS;

EID: 33751088786     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.1609     Document Type: Article

References (49)

1. Agnoli A. 1985. Studio policentrico acetil-L-carnitina nei confronti di placebo in pazienti geriatrici. Risultati preliminari. Abstract in the IVth World Congress of Biological Psychiatry, Philadelphia, USA, 8-13 September.
2. Agnoli A. 1994. Controlled Clinical Study with Acetyl-L-Carnitine versus Placebo in Geriatric Patients. Statistical Report, Study Protocol No: DRN-PS-84. On file Sigma-Tau.
3. Bassi S, Ferrarese C, Finoia M. 1988. L-acetylcarnitine in Alzheimers disease and senile dementia Alzheimer type. In Senile Dementia, Agnoli A, Cahn J, Lassen N, Mayeux R (eds). John Libbey: Paris; 461-466.
4. Battistin L, Pizzolato G, Dam M, et al. 1989. Effects of acetyl-L-carnitine (ALC) treatment in dementia: a multicentric, randomized, double-blind study. New Trends Clin Neuropharmacol 3: 131-132.
5. Bayer A. 1994. The Effect of Acetyl-L-Carnitine in Senile Dementia of the Alzheimer Type Clinical Report, Study Protocol No.: S104/1 CT4. On file Sigma-Tau.
6. Bellagamba G. 1991. Efficacy of Acetyl-L-Carnitine in Patients with Degenerative Dementia (SDAT)/ Statistical Report, Study Protocol No.: DRN5-005. On file Sigma-Tau.
7. Bellagamba G, Postacchini D, Moretti V, Pennacchietti L. 1990. Acetyl-LCarnitine activity in Senile Dementia Alzheimer type. Neurobiol Aging 11: 345.
8. Bertolino A, Papagno G. 1983. Attività della L-acetil carnitina nel deterioramento mentale. Clin Europ 2: 384-395.
9. Cucinotta D, Passeri M, Ventura S, et al. 1988. Multicenter clinical placebo-controlled study with acetyl-L-carnitine (LAC) in the treatment of mildly demented elderly patients. Drug Devel Res 14: 213-216.
10. Devanand DP, Marder K, Michaels KS, et al. 1998. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry 155: 1512-1520.
11. Frattola L. 1991. L-Acetyl Carnitine in Alzheimer Disease (A.D.) and Senile Dementia Alzheimer Type (SDAT). Statistical Report, Study Protocol No.: DRN2-005. On file Sigma-Tau.
12. Frattola L, Meregalli S, Bassi S, et al. 1988. L-Acetyl-carnitine activity on SDAT patients. Abstract in Cognition enhancers: from animal to man. Second International Symposium on preclinical strategies in psychopharmacology, Paris.
13. Frisoni GB: Centro Alzheimer [Centro Alzheimer web site]. Available at: http://www.centroalzheimer.it/ricuva.htm; accessed November 24, 2005.
14. Frisoni GB. 2004. Diagnosi e Terapia della malattia di Alzheimer: Un percorso per le Unità di Valutazione Alzheimer. Ed. Fatebenefratelli.
15. Frisoni GB, Padovani A, Wahlund LO. 2004. The predementia diagnosis of Alzheimer disease. Alzheimer Dis Assoc Disord 18: 51-53.
16. Giuliani A, Calvani M. 1990. Abstract in the XVII Congress of Collegium Internationale Neuro-Psychopharmacologicum, Kyoto, Japan, 10-14 September.
17. Herrmann WM. 1988. Demonstration of the effects of Acetyl-L-Carnitine on impaired brain functions in geriatric outpatients. Clinical Report, Study Protocol No: KFB820-86. On file Sigma-Tau.
18. Herrmann WM, Dietrich B, Hiersemenzel R. 1990. Pharmacoelectroencephalographic and clinical effects of the cholinergic substance Acetyl-L-Carnitine in patients with organic brain-syndrome. Int J Clin Pharmacol Res 10: 81-84.
19. James IM. 1992. The Effect of Acetyl-L-Carnitine in Senile Dementia of Alzheimer type. Statistical Report, Study Protocol No.: S.104/1 CT1. On file Sigma-Tau.
20. Katz IR, Jeste DV, Mintzer JE, et al. 1999. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 60: 107-115.
21. Livingston GA, Sax KB, McClenahan Z, et al. 1991. Acetyl-L-carnitine in dementia. Int J Geriat Psychiatry 6: 853-860.
22. Lopez OL, Becker JT, Klunk W, et al. 2000. Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades. Neurology 55: 1854-1862.
23. Lyketsos CG, Sheppard JM, Steele CD, et al. 2000. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. Am J Psychiatry 157: 1686-1689.
24. Lyketsos CG, Lopez O, Jones B, et al. 2002. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 288: 1475-1483.
25. Mantero MA. 1991. Effects of Acetyl-L-Carnitine Treatment in Geriatric Patients Suffering From Mental Deterioration (Double-Blind Placebo Controlled Study). Statistical Report, Study Protocol No.: DRN2-002. On file Sigma-Tau.
26. Mantero MA, Barbero M, Giannini R, et al. 1989. Acetyl-L-carnitine as a therapeutic agent for mental deterioration in geriatric patients. (double-blind placebo controlled study). New Trends Clin Neuropharmacol 3: 17-24.
27. Ministero della Salute-Medicinali e Vigilanza-Informazione sui Farmaci [Ministero della salute web site]. Available at: www.alzheimer-cronos.it; http://www.ministerosalute.it/imgs/C_17_ notaInf_1_listaFile_itemName_0_file.pdf; http://www.ministerosalute.it/ imgs/C_17_notaInf_1_listaFile_itemName_1_file.pdf.; Accessed November 24, 2005.
28. Montgomery SA, Thal LJ, Amrein R. 2003. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol 18: 61-71.
29. Mullin K. 1994. The Effect of Acetyl-L-Carnitine in Senile Dementia of the Alzheimer Type Clinical Report, Study Protocol No.: S104/1 CT3. On file Sigma-Tau.
30. Nyth AL, Gottfries CG, Lyby K, et al. 1992. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 86: 138-145.
31. Onofrj. 1992. Evaluation of Efficacy of Chronic Administration (6 Months) of Acetyl-L-Carnitine in Patients Suffering from Senile Dementia Alzheimer Type (SDAT) and Alzheimer Disease (AD) Statistical Report, Study Protocol No.: ST20032189 (DRN4-021). On file Sigma-Tau.
32. Oude Voshaar RC, Burns A, Olde Rikkert MG. 2006. Alarming arbitrariness in EU prescription and reimbursement criteria for anti-dementia drugs. Int J Geriatr Psychiatry. 21: 29-31.
33. Passeri M, Cucinotta D, Bonati PA, et al. 1990. Acetyl-L-carnitine in the treatment of mildly demented elderly patients. Int J Clin Pharmacol Res 10: 75-79.
34. Petersen RC, Smith GE, Waring SC, et al. 1999. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56: 303-308.
35. Petersen RC, Doody R, Kurz A, et al. 2001. Current concepts in mild cognitive impairment. Arch Neurol 58: 1985-1992.
36. Petersen RC, Thomas RG, Grundman M, et al. and the Alzheimer's Disease Cooperative Study Group. 2005. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352: 2379-2388.
37. Pettegrew JW, Klunk WE, Panchalingam K, et al. 1995. Clinical and neurochemical effects of Acetyl-L-Carnitine in Alzheimers disease. Neurobiol Aging 16: 1-4.
38. Rai G. 1989. Double-Blind Placebo-Controlled Parallel-Group Study of the Efficacy and Tolerability of Acetyl-L-Carnitine in Elderly Patients with Mild to Moderate Dementia of Alzheimer's Type. Clinical Report, Study Protocol No.: S104/1 CT2. On file Sigma-Tau.
39. Rai G, Wright G, Scott L, et al. 1990. Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia. Curr Med Res Opin 11: 638-647.
40. Raschetti R, Maggini M, Sorrentino GC, et al. 2005. A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. Eur J Clin Pharmacol 61: 361-368.
41. Rotmensch. 1993. Efficacy and Safety of Acetyl-L-Carnitine versus Placebo upon Long-Term Treatment in Elderly Patients with Senile Dementia Alzheimer Type Clinical Report, Study Protocol No.: 09/0181-89. On file Sigma-Tau.
42. Salloway S, Ferris S, Kluger A, et al. 2004. Donepezil 401 Study Group. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 63: 651-657.
43. Sano M, Bell K, Cote L, et al. 1992. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease. Arch Neurol 49: 1137-1141.
44. Seat Pagine Gialle S.p.A.: Telephone register [Pagine bianche and Pagine gialle web site]. Available at: http://www.paginebianche.it; http://www.paginegialle.it; Accessed November 24, 2005.
45. Spagnoli A, Lucca U, Menasce G, et al. 1991. Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology 41: 1726-1732.
46. Street JS, Clark WS, Gannon KS, et al. 2000. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 57: 968-976.
47. Thal LJ, Carta A, Clarke WR, et al. 1996. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology 47: 705-711.
48. Thal LJ, Calvani M, Amato A, Carta A. 2000. A 1-year controlled trial of acetyl-Lcarnitine in early-onset AD. Neurology 55: 805-810.
49. Toth E, Harsing LGJr, Sershen H, et al. 1993. Effect of acetyl-L-carnitine on extracellular amino acid levels in vivo in rat brain regions. Neurochem Res 18: 573-578.